Release issued 15th October 1999

TransDermal Technologies, Inc. announced today the release of the latest pre-clinical data validating its patent-pending, patchless liquid transdermal delivery system, TDS(tm) in the delivery of Cystamine.

The study, overseen by Prof. Derek Willoughby and completed by Dr. Chandan A.S. Alam, M.D. of the Department of Experimental Pathology at the William Harvey Institute at St. Bartholomew's and the Royal London School of Medicine and Dentistry measured the ability of the TDS technology to deliver Cystamine through the skin in a sufficient dose to accomplish a therapeutic outcome without a patch or other appliance. Data from the study confirmed company claims that the TDS technology enables rapid penetration and increased blood concentrations of the drug as well as rendering a normally sub-effective dose effective. The model for the study was the Murine Chronic Granulomatous Air Pouch (Kimura et alia, 1985) in white mice. The rodent air pouch results in a granuloma that resembles the inflammed pouch of synovial fluid surrounding an arthritic joint. In addition to studies examining the similarities between cells in synovial fluid and air pouch lining cells, the air pouch has been further developed in mice for examiniation of angiogenesis, i.e. the development of new blood vessels to an inflammed area, a phenomenom that is closely linked to the growth of cancerous tumors.

In this study, granulomas were created with the Air Pouches and then treated with four different solutions including (1) a control vehicle alone, (2) the control vehicle with 30 mg/kg of animal weight of Cystamine, (3) the TDS without Cystamine and (4) the TDS with 30 mg/kg Cystamine. The results indicated that the TDS is indeed delivering the Cystamine and in fact, with the TDS, the normally sub-effective dose of 30 mg/kg of Cystamine was rendered effective as measured by the decrease in dry weight of the granulomas.

In light of these encouraging results, Dr. Alam suggests the TDS Cystamine should be tested in a tumor model. If such a subsequent study proves that the TDS Cystamine effectively impacts a tumor, then further studies of other known, effective anti-tumor compounds would be indicated.

TransDermal Technologies is actively seeking a licensing partner interested in exploiting this technology.

TransDermal Technologies' TDS is a platform system that is designed to be modified for each application and is believed to enable the rapid, safe and effective delivery of many medicaments across intact skin by means of its sprayed-on lotions. The Company is currently testing Testosterone, Morphine HCL and Acyclovir in pre-clinical trials at the William Harvey Institute in London.

Company Contact: Kenneth B. Kirby - tti@gateway.net / 800-282-5511 / 561-848-9100

(30th May 2009) NSAID DANGERS COULD BE REDUCED WITH TDS (R) DELIVERY

(15th May 2009) TDS® TESTOSTERONE WILL LIKELY NOT REQUIRE BLACK BOX WARNINGS FROM FDA

(25th April 2009) TDS® TESTOSTERONE EXCEEDS ANDROGEL® OUTCOMES

(15th March 2009) TTI's LANGFORD RESEARCH PARTNERS WITH SCI

(5th January 2009) TTI'S LANGFORD RESEARCH INSTITUTE TO OCCUPY LAB SPACE